The Marie Curie Palliative Care Institute

LIVERPOOL

Liverpool Care Pathway for the Dying Patient (LCP)

National LCP Renal Steering Group

Guidelines for LCP Drug Prescribing in Advanced Chronic Kidney Disease (estimated glomerular filtration rate < 30 ml/min)

**June 2008** 

## **ENDORSED BY:**





The Renal Association



The Royal Liverpool and **NHS** Broadgreen University Hospitals





### DH INFORMATION READER BOX

DH INFORMATION R			
Policy	Estates		
HR / Workforce			
Management Planning /	IM & T Finance		
Clinical	Social Care / Partnership Working		
Document Purpose	Best Practice Guidance		
Gateway Reference	8611		
Title	Guidelines for LCP Prescribing in Advanced Chronic Kidney Disease		
Author	DH Renal NSF Team and Marie Curie Palliative Care Institute		
Publication Date	01 May 2008		
Target Audience	GPs, Renal Clincial Directors, British Renal Society Council Members, Renal Pharmacy Group Members, Renal Nursing Group Members, Pharmacisst, Specialist Palliative Care Teams, End of Life Care Leads, staff in Renal Units.		
Circulation List			
Description	Letter on Renal End of Life Care enclosing link to Prescribing Guidelines		
Cross Ref	National Service Framework for Renal Services Part 2		
Superseded Docs	n/a		
Action Required	To note and consider best practice		
Timing	n/a		
Contact Details	Jane Heaton Renal and Vascular Policy Manager Department of Health Room 403 Wellington House 133-155 Waterloo Road London SE1 8UG tel: 020 7972 1047 www.dh.gov.uk/renal		
For Recipient's Use			

# Foreword

Recent advances in the treatment of renal failure have meant that many patients are now surviving for longer, and with increased quality of life, due to renal replacement therapies and kidney transplants. Over 50% of the best-matched kidney transplants are still functioning after twenty-five years and some patients can survive for over twenty years on dialysis. But for those patients in whom such interventions are not appropriate or no longer effective, the shift to palliative care should be encouraged to maintain a good quality of life in dying patients

In 2005 a National LCP Renal Steering Group was developed and utilised an action research approach that has been used to facilitate the transferability of the LCP for use in these more specialist renal areas. This excellent programme included the design of patient and carers information, professional guidance and this innovative and much needed drug guidance for patients with advanced and chronic kidney disease in the last days of life.

This guidance will be welcomed by all specialists and generalists working to ensure models of best practice in the last days of life. The authors have provided clear guidance and advice on medicines management and the control of distressing symptoms. It will enable the service to respond to and respect the wishes of patients and their carers.

All patients with advanced chronic kidney disease deserve optimum care in the last days of life. I believe the LCP and this associated guidance provides us with a significant step towards providing a model of excellence.

Daral J. O'Dara

Dr Donal O'Donoghue National Clinical Director for Kidney Care, Department of Health

Introduction	Page 4
Pain Guidelines	Page 5
Opioid Conversion Table	Page 6
<i>Terminal restlessness and agitation</i> <i>Guidelines</i>	Page 7
Respiratory tract secretions Guidelines	Page 8
Nausea and Vomiting Guidelines	Page 9
Dyspnoea Guidelines	Page 10
Project Group	Page 11-12
Bibliography	Page 13
Contact Details	Page 14

# Contents

# Introduction

It is recognised that most patients with kidney disease do not die directly from kidney failure, but from other medical problems. However renal impairment, even if not the primary problem, is an important consideration when considering prescribing drugs in these patients. This is particularly the case for opioids, as metabolites can and do accumulate in renal impairment and may lead to significant toxicity if this is not recognised. These guidelines are designed to optimise the risk/benefit ratio of these drugs. However, it is important to be aware that the risks of toxicity and side effects increase cumulatively as GFR falls. These guidelines are aimed at controlling symptoms once it is recognised that the patient is dying and in the last few days of life. Usually at this stage, the patient will require medication to be given by the subcutaneous route.

### Prescribing in Advanced Chronic Kidney Disease

The evidence for symptom control in the dying patient is limited and therefore all of the guidelines are based on level 3 and 4 evidence and expert opinion (**DoH 2005**).

In general, most medications are not excreted well in advanced Chronic Kidney Disease (CKD). It is therefore important to choose medication least likely to accumulate and cause adverse effects. Drug doses may require reduction and dosing intervals may need to be increased to reduce drug toxicity.

Once administered, a drug may have a longer duration of effect than expected and therefore PRN or regular doses of drugs may need to be given less often.

With regard to management of pain and dyspnoea, the evidence for the use of opioids in renal failure is limited. However, these guidelines aim to provide symptom control safely and without development of opioid toxicity. It is very important to titrate the medication carefully and frequently review the patient as considerable variation between patients can exist.

These guidelines were produced by the National LCP Renal Steering Group based on level 3 and 4 evidence and expert opinion. If you would like to refer to this in your clinical practice may we suggest that you liaise with your local drugs & therapeutics – pharmacy policy & procedure, which will determine safe practice & prescribing protocols within your clinical area


We also suggest that liaison between the Hospital Specialist Palliative Care Team, End of Life Care Leads & Conservative Management Renal Leads is key in caring for patients with advanced CKD in the last hours & days of life.

E Ellerhaus

**Professor John Ellershaw** Director – Marie Curie Palliative Care Institute Liverpool National Clinical Lead Palliative Care – (Specialist)

Claire A Darfas

**Dr Claire Douglas** SpR in Palliative Medicine Chair – Expert Consensus Group



#### SUPPORTIVE INFORMATION:

- To convert from other strong opioids contact Specialist Palliative Care Team / Pharmacy for further advice & support as needed
- \* If Fentanyl is temporarily unavailable give:

Oxycodone 1-2 milligrams S/C prn or Morphine 1.25 – 2.5 milligrams S/C PRN


- Many of the opioid analgesics and their metabolites may accumulate in Renal Failure causing toxicity with
  myoclonic jerks, profound narcosis and respiratory depression. Morphine and its metabolites are most likely to
  cause toxicity. Fentanyl and Alfentanil are less likely to cause these problems, as the metabolites are not active.
  The duration of effect from Morphine and Oxycodone may last longer than in a patient with normal renal
  function. (See conversion table on Page 5)
- If Fentanyl dose exceeds 500 micrograms in a Syringe Driver seek expert advice for conversion to Alfentanil
- If symptoms persist contact the Specialist Palliative Care Team
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs
- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base

#### **OPIOID CONVERSION TABLE**

Opioid equivalent doses (Note: There is no exact equivalence between opioids therefore starting low and titrating upwards is recommended safe practice)


ORAL MORPHINE	DIAMORPHINE INJECTION	MORPHINE INJECTION	FENTANYL INJECTION	ALFENTANIL INJECTION	OXYCODONE INJECTION
4 milligrams	1.25 milligrams	2 milligrams	25 micrograms	125 micrograms	1 milligram
orally	subcutaneously	subcutaneously	subcutaneously	subcutaneously	subcutaneously
3 milligrams	2.5 milligrams	4 milligrams	50 micrograms	250 micrograms	2 milligrams
orally	subcutaneously	subcutaneously	subcutaneously	subcutaneously	subcutaneously
				Note: alfentanil is not	
				ideal for prn use since it	
				has a very short half life,	
				and doses may only last	
				1-2 hours	
Starting doses in addition to t	the continuous infusion	or opioid requiremer – there is no upper l	nts, and titrated upwar imit provided the pain	ds according to the amount is responding well to the opi	ioid, and there are no symptoms
(Starting doses <i>in addition</i> to t	should be based on pri the continuous infusion rse effects or toxicity. M	or opioid requiremer – there is no upper l ost patients with ren fro	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care	ds according to the amount is responding well to the op low doses – if the dose is es team)	of subsequent PRN doses requir ioid, and there are no symptoms calating, advice should be sough
(Starting doses <i>in addition</i> to t	should be based on pri the continuous infusion	or opioid requiremer – there is no upper l ost patients with ren	nts, and titrated upwar imit provided the pain al failure require only l	ds according to the amount is responding well to the op low doses – if the dose is es	ioid, and there are no symptoms
Starting doses in addition to t	should be based on pri the continuous infusion rse effects or toxicity. M DIAMORPHINE	or opioid requiremer – there is no upper I ost patients with ren fro MORPHINE	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION 100 – 200	ds according to the amount is responding well to the opi low doses – if the dose is es team) ALFENTANIL INJECTION 500 micrograms - 1	ioid, and there are no symptoms calating, advice should be sough
Starting doses in addition to t	should be based on pri the continuous infusion rse effects or toxicity. M DIAMORPHINE INJECTION	or opioid requiremer – there is no upper I ost patients with ren. fro MORPHINE INJECTION	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION	ds according to the amount is responding well to the opt low doses – if the dose is es team) ALFENTANIL INJECTION	ioid, and there are no symptoms calating, advice should be sough OXYCODONE INJECTION
Starting doses in addition to	should be based on pri- the continuous infusion rse effects or toxicity. M DIAMORPHINE INJECTION 5 - 10 milligrams	or opioid requiremer – there is no upper I ost patients with ren fro MORPHINE INJECTION 8 - 16 milligrams	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION 100 – 200	ds according to the amount is responding well to the opi low doses – if the dose is es team) ALFENTANIL INJECTION 500 micrograms - 1	ioid, and there are no symptoms calating, advice should be sough OXYCODONE INJECTION
Starting doses in addition to	should be based on pri the continuous infusion rse effects or toxicity. Me DIAMORPHINE INJECTION 5 - 10 milligrams Do not use	or opioid requiremer – there is no upper I ost patients with ren fro MORPHINE INJECTION 8 - 16 milligrams Do not use	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION 100 – 200	ds according to the amount is responding well to the opi low doses – if the dose is es team) ALFENTANIL INJECTION 500 micrograms - 1	ioid, and there are no symptoms calating, advice should be sough OXYCODONE INJECTION
Starting doses in addition to t	should be based on pri the continuous infusion rse effects or toxicity. M DIAMORPHINE INJECTION 5 - 10 milligrams Do not use diamorphine in	or opioid requiremer – there is no upper I ost patients with ren- fro <b>MORPHINE</b> <b>INJECTION</b> 8 - 16 milligrams Do not use morphine in	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION 100 – 200	ds according to the amount is responding well to the opi low doses – if the dose is es team) ALFENTANIL INJECTION 500 micrograms - 1	ioid, and there are no symptoms calating, advice should be sough OXYCODONE INJECTION
Starting doses in addition to	should be based on pri- the continuous infusion rse effects or toxicity. Me DIAMORPHINE INJECTION 5 - 10 milligrams Do not use diamorphine in continuous	or opioid requiremer – there is no upper I ost patients with ren fro <b>MORPHINE</b> <b>INJECTION</b> 8 - 16 milligrams Do not use morphine in continuous	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION 100 – 200	ds according to the amount is responding well to the opi low doses – if the dose is es team) ALFENTANIL INJECTION 500 micrograms - 1	ioid, and there are no symptoms calating, advice should be sough OXYCODONE INJECTION
(Starting doses <i>in addition</i> to t	should be based on pri the continuous infusion rse effects or toxicity. Me DIAMORPHINE INJECTION 5 - 10 milligrams Do not use diamorphine in continuous infusion because of the high risk of accumulation and	or opioid requiremer – there is no upper I ost patients with ren fro MORPHINE INJECTION 8 - 16 milligrams Do not use morphine in continuous infusion because of the high risk of accumulation	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION 100 – 200	ds according to the amount is responding well to the opi low doses – if the dose is es team) ALFENTANIL INJECTION 500 micrograms - 1	ioid, and there are no symptoms calating, advice should be sough OXYCODONE INJECTION
(Starting doses <i>in addition</i> to t	should be based on pri- the continuous infusion rse effects or toxicity. Me DIAMORPHINE INJECTION 5 - 10 milligrams Do not use diamorphine in continuous infusion because of the high risk of	or opioid requirement – there is no upper lost patients with rem <b>MORPHINE</b> <b>INJECTION</b> 8 - 16 milligrams Do not use morphine in continuous infusion because of the high risk of	nts, and titrated upwar imit provided the pain al failure require only om the Palliative Care FENTANYL INJECTION 100 – 200	ds according to the amount is responding well to the opi low doses – if the dose is es team) ALFENTANIL INJECTION 500 micrograms - 1	ioid, and there are no symptoms calating, advice should be sough OXYCODONE INJECTION

# Terminal restlessness and agitation



#### SUPPORTIVE INFORMATION:


- If symptoms persist contact the Specialist Palliative Care Team
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs.
- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base



#### **SUPPORTIVE INFORMATION:**

- If symptoms persist contact the Specialist Palliative Care Team
- Hyoscine butylbromide 20 milligrams s/c prn may be used as an alternative. (If a S/C Syringe Driver is required then consider Hyoscine butylbromide 40 120 milligrams over 24 hours)
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs.
- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base


Hyoscine Hydrobromide is not usually recommended



#### SUPPORTIVE INFORMATION;

- If symptoms persist contact the Specialist Palliative Care Team
- Levomepromazine 6.25 milligrams S/C prn *suitable alternative second line* (if a Syringe Driver is required then consider 6.25 milligrams S/C in a Syringe Driver over 24 hours)
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs.
- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base

Cyclizine is not usually recommended



#### **SUPPORTIVE INFORMATION:**

- If symptoms persist contact the Specialist Palliative Care Team
- To convert from other strong opioids contact Specialist Palliative Care Team / Pharmacy for further advice & support
- If the patient is breathless and anxious consider Midazolam 2.5 milligrams S/C prn
- \* If Fentanyl is temporarily unavailable give:

Oxycodone 1-2 milligrams S/C prn or Morphine 1.25 – 2.5 milligrams S/C PRN

- Many of the opioid analgesics and their metabolites may accumulate in Renal Failure causing toxicity with
  myoclonic jerks, profound narcosis and respiratory depression. Morphine and its metabolites are most
  likely to cause toxicity. Fentanyl and Alfentanil are less likely to cause these problems, as the metabolites
  are not active. The duration of effect from Morphine and Oxycodone may last longer than in a patient with
  normal renal function. (See conversion table on Page 5)
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay
  responding to a symptom if it occurs
- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base

#### PROJECT GROUP

These guidelines have been produced by the National Liverpool Care Pathway for the Dying Patient (LCP) Renal Steering Group building on recent work undertaken by the Merseyside & Cheshire Palliative Care Network Audit Group.

#### This work has been led by:

Dr Claire Douglas, Specialist Registrar in Palliative Medicine at Mersey Deanery

#### Supported by:

- Merseyside & Cheshire Palliative Care Network Audit Group Renal Audit
- National Liverpool Care Pathway for the Dying Patient (LCP) Renal Steering Group

#### Expert Consenus Group

Dr Claire A Douglas	SpR in Palliative Medicine	Mersey Deanery
Dr Stephanie Gomm	Consultant in Palliative Medicine	Salford Royal Foundation NHS Trust
Dr Jo Chambers	Consultant in Palliative Medicine	North Bristol NHS Trust
Dr Matthew Howse	Consultant Nephrologist	Royal Liverpool & Broadgreen University Hospitals NHS Trust
Dr Polly Edmonds	Consultant in Palliative Medicine	Kings College Hospital NHS Trust
Dr Fliss Murtagh	SpR Research Training Fellow	Kings College Hospital NHS Trust
Dr Alistair Chesser	Consultant Nephrologist	Barts and the London NHS Trust
Dr Martine Meyer	Consultant in Palliative Medicine	Epsom & St Helier Hospitals NHS Trust

#### National Liverpool Care Pathway for the Dying Patient (LCP) Renal Steering Group

Name	Title			
Marie Curie Palliative Care Institute Liverpool (MCPCIL)				
Prof John Ellershaw	Director			
Deborah Murphy	Associate Director			
Dr Claire Douglas	SpR in Palliative Medicine			
Maria Bolger	LCP Facilitator			
Ruth Agar	Associate LCP Facilitator			
Maureen Gambles	Senior Research Fellow			
Debbie Griffiths	External Events Coordinator – LCP Framework			
Sian Edwards	Programme Administrator			
Tamsin McGlinchey	Research Assistant			
Kate Richardson	Research Assistant			
Dr James Stevenson	SpR in Palliative Medicine			
Elaine Whitby	Project Director, Education Pilot Project			
Gill Hamblin	Non-Cancer Programme Lead			
National Council for Palliative Care				
Eve Richardson	Chief Executive			
Cheshire & Merseyside Strategic Health Authority				
Anita Roberts	End of Life Care Programme Lead			
Cathy Wilcox	End of Life Care Deputy Programme Lead			
North Bristol NHS Trust				
Dr Jo Chambers	Consultant in Palliative Medicine			
Dr Colette Reid	SpR in Palliative Medicine			
Marika Hills	Integrated Care Pathway Coordinator			
Patsy Naidoo	Staff Nurse			
Ann Banks	Staff Nurse - Renal ICP Link Nurse			
Central Manchester & Manchester Children's University Hospital NHS Trust				
Sue Heatley	Pre Dialysis Nurse Specialist			

Salford Royal Foundation NHS Trust				
Dr Stephanie Gomm	Consultant in Palliative Medicine / National Clinical			
	Champion(LCP)			
Bernadette Wilcox	Palliative Care CNS			
Dr David New	Consultant Renal Physician			
Cath Byrne	Pathway Facilitator			
Royal Liverpool & Broadgreen University Hospitals NHS Trust				
Dr Matthew Howse	Consultant Nephrologist			
	/irral Hospitals NHS Trust			
Dr Cathy Lewis-Jones	Consultant in Palliative Medicine			
Sandra Rowlands	Liverpool Care Pathway for the Dying Facilitator			
Sheila Nugent	Palliative Care CNS			
Hayley Lloyd	Renal Nurse			
Sue Peters	Renal Nurse			
King	s College Hospital NHS Trust			
Dr Polly Edmonds	Consultant in Palliative Medicine			
Dr Fliss Murtagh	SpR Research Training Fellow			
Mary Preston	Liverpool Care Pathway Lead			
	smouth Hospitals NHS Trust			
Kay McConville	LCP Facilitator			
Angela Devonport	Modern Matron – Renal			
	olverhampton NHS Trust			
Pam Magee	Director of Pharmaceutical Services			
Bart	s and the London NHS Trust			
Dr Alistair Chesser	Consultant Nephrologist			
Teresa Coyne	Macmillan Palliative Care CNS / LCP Lead			
Pat Langstone	Macmillan Palliative Care CNS			
Epsom	& St Helier Hospitals NHS Trust			
Dr Martine Meyer	Consultant in Palliative Medicine			
Valerie Crooks	LCP Facilitator			
National Kidney Federation				
Tim Statham	Chief Executive			
Robert Dunn	National Advocacy Officer			
Dudley	Group of Hospitals NHS Trust			
Dr Ruth Benzimra	Consultant Nephrologist			
	Department of Health			
Sue Hawkett OBE	Nursing Adviser / Team Leader (Supportive & Palliative			
	Care) Cancer Policy Team			
Claire Henry	Programme Director National End of Life Care Programme			
Jane Verity	Renal NSF Team			
Gerry Lynch	Team Leader Renal NSF			
	n & Sussex Hospitals NHS Trust			
Dr Andreas Hiersche	Macmillan Consultant Palliative Care			
St Catherine's Hospice, Scarborough				
Dr Miriam Johnson	Consultant in Palliative Medicine			

### **BIBLIOGRAPHY**

Bunn R, Ashley A, (eds). The Renal Handbook. Oxford: Radcliffe Medical Press; 2004.

Chambers EJ, Germain M, Brown E, (eds). *Supportive Care for the Renal Patient*. Oxford. Oxford University Press; 2004.

Davison S. Chronic Pain in End Stage Renal disease. Adv Chronic Kidney Dis 2005; 12(3): 326-334.

Dean M. Opioids in Renal Failure and Dialysis Patients. *J Pain Symptom Manage* 2004; **28(5)**: 497-504.

Department of Health. The National Service Framework for Renal Services Part Two: Acute Renal Failure Chronic Kidney Disease, and End of Life. London 2005.

Humphreys BD, Soiffer RF, Magee CC. Renal failure associated with cancer and its treatment: An update. *J Am Soc Nephrol* 2005: **16**: 151-161.

Kurella M, Bennett WM, Chertow GM. Analgesia in Patients with End Stage renal Disease: A Review of Available Evidence. *Am J Kidney Dis* 2003, **42(2)**: 217-228.

Mercadante S, Arcuri E. Opioids and Renal Function. J Pain 2004, 5(1): 2-19.

Murtagh F, Addington-Hall J, Higginson I. The Prevalence of Symptoms in End-Stage Renal Disease: A Systematic Review. *Advances in Chronic Kidney Disease*. 2007; 14(1):82-99

Scholz J, Steinfath M, Schulz M. Clinical Pharmacokinetics of Alfentanil, Fentanyl and Sufentanil. An Update. *Clin. Pharmacokinetics*. 1996; 31(4): 275-292

Urch CE, Carr S, Minton O. A retrospective review of the use of alfentanil in a hospital palliative care setting. *Palliat Med* 2004; **18(6)**: 385-387.

US Food and Drug Administration [homepage on the Internet]. Rockville MD: Details View: Safety Labelling Changes Approved by FDA Centre for Drug Evaluation and research. [Updated 2006 Jan; accessed 2006 May 11]. Available from <u>http://www.fda.gov/medwatch/safety/2006/jan06.htm</u>

### **CONTACT DETAILS**

Should you wish to contact the Marie Curie Palliative Care Institute Liverpool, then please see the contact details below

Professor John Ellershaw Director Marie Curie Palliative Care Institute Liverpool c/o Marie Curie Hospice Liverpool Speke Road, Woolton Liverpool L25 8QA

- T: 0151 801 1490
- E: john.ellershaw@mariecurie.org.uk

Deborah Murphy Associate Director Marie Curie Palliative Care Institute Liverpool c/o Directorate of Specialist Palliative Care 1<sup>st</sup> Floor, Linda McCartney Centre The Royal Liverpool and Broadgreen University Hospitals Prescot Street Liverpool L7 8XP

- T: 0151 706 2274
- E: deborah.murphy@rlbuht.nhs.uk

### **USEFUL WEBSITES**

Marie Curie Palliative Care Institute Liverpool

Department of Health

The Renal Association

**British Renal Society** 

End of Life Care Programme

www.mcpcil.org.uk www.dh.gov.uk www.renal.org www.britishrenal.org www.endoflifecare.nhs.uk

Marie Curie Palliative Care Institute Liverpool www.mcpcil.org.uk